Experimental study of state of gastric mucosa in rats under introduction of new derivate of 4-[4-oxo-4h-quinazoline-3-yl] benzoic acid (PC-66)

Authors

DOI:

https://doi.org/10.15587/2519-4852.2017.100549

Keywords:

4- [4-oxo-4H-quinazoline-3-yl] benzoic acid, gastrotoxicity, PGH – synthetase, NO metabolites

Abstract

Screening studies have revealed that the new derivate of 4-[4-oxo-4H-quinazoline-3-yl] benzoic acid (compound PC-66) possess significant antinociceptive and weakly expressed anti-inflammatory and antipyretic activity on different models of pain and inflammation. The cоndition of gastric defense under influence of PC-66 is unknown.

The aim of this study was to explore the ability of PC-66 in comparison with diclophenac sodium produce gastric lesions on intact and rats with adjuvant arthritis, and to determine the role of influence on prostaglandin–H-synthase and stable metabolits of nitric oxide in the pathogenesis of these damages.

Materials and methods: The impact of PC-66 compound and a diclofenac sodium was explored on macroscopic changes in gastric mucosa under conditions of long-term administration and of experimental inflammation.

The spectrophotometric method revealed active prostaglandin-endoperoxide synthase in the rats` GM homogenates against accumulation of oxidized form of adrenaline electron donor. The total content of nitrites and nitrates was determined by reaction with Griess reagent after preliminary restoration of nitrates with a suspension of zinc dust in ammonia solution.

Results and Discussion. PC-66 compound, unlike the reference medicine, did not cause significant gastric lesions under conditions of its long-term administration to intact rats. We found that during diclofenac administration, the activity of PGH-synthetase in GM significantly decreased compared to the control, whilst under the influence of PC-66, the activity of this enzyme remained practically unchanged. Administration of PC-66 compound to rats, unlike diclofenac, was associated with a significant increase of stable NO metabolites in GM, whilst this index decreased compared to control under the influence of investigational NSAID.

Conclusions: 4- [4-oxo-4H-quinazoline-3-yl] benzoic acid has no damaging effect on the gastric mucosa both in intact animals and in rats with experimental inflammation. The basis of its GM safety rests on lacking inhibitory effect on production of vasodilator molecules in GM of PC-66 compound, unlike diclofenac sodium

Author Biography

Hanna Kramar, National Pirogov Memorial Medical University; Pirogova str., 56, Vinnitsa, Ukraine, 21000

assistant

Department of Pharmacy 

References

  1. Palmer, G. M. (2016). Pain management in the acute care setting: Update and debates. Journal of Paediatrics and Child Health, 52 (2), 213–220. doi: 10.1111/jpc.13134
  2. Karateev, A. E. (2015). Modyfikatsyia tradytsionnykh NPVP kak metod povysheniia ikh bezopasnosti i udobstva prymeneniia [Modification of traditional NSAID as a method to increase their safety and usability]. RMJ Rheumatology, 7, 392–399.
  3. Tarnawski, A. S., Ahluwalia, A., Jones, M. K. (2012). The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target. Current Medicinal Chemistry, 19 (1), 4–15. doi: 10.2174/092986712803414079
  4. Khodakivskyi, O. A. (2009). Neiroprotektorna diia pokhidnykh 4-okso(amino-) khinazolinu pry eksperymentalnii ishemii holovnoho mozku. Odes'kyi derzhavnyi medychnyi universytet. Odessa, 21.
  5. Stepaniuk, G. I., Alchuk, O. I., Shevchuk, O. K. et. al. (2009). Skryninh aktoprotektornoi aktyvnosti sered pokhidnykh 4­okso(amino)­khinazolinu [Screening act protective activity among derivatives 4okso (amino) quinazoline]. Zdobutky klinichnoi i eksperymentalnoi medytsyny, 1, 85–88.
  6. Pavlov, S. V. (2007). Tserebroprotektyvna aktyvnist pokhidnykh (4-okso-4-N-khinazolin-3-il)-alkil (aryl) karbonovykh kyslot v umovakh imobilizatsiinoho stresu [Cerebral protective derivatives activity (4-oxo-4-H-quinazolin-3-yl) -alkyl (aryl) carboxylic acids under conditions of stress immobilization]. Kyiv, 17.
  7. Yurchenko, A. I. (2013). Skryninh analhetychnoi dii pokhidnykh 4-okso(amino-) khinazolinu [Screening of analgesic effect of 4-oxo (amino) quinazoline]. Pharmacology and Drug Toxicology, 2 (33), 89–91.
  8. Kemmerly, T., Kaunitz, J. D. (2014). Gastroduodenal mucosal defense. Current Opinion in Gastroenterology, 30 (6), 583–588. doi: 10.1097/mog.0000000000000124
  9. Stefanov, O. V. (Ed.) (2001). Doklinichni doslidzhennia likarskykh zasobiv [Preclinical studies of drugs]. Kyiv: Avitsena, 528.
  10. Mevkh, A. T., Basevych, Y. Y., Varfolomeev, S. D. (1982). Izuchenie endoperoksydprostahlandynsyntetazy mykrosomnoi fraktsyy trombotsytov cheloveka [Study endoperoksidprostaglandinsintetazy microsomal fraction of human platelets]. Biohimija, 47 (10), 1635–1639.
  11. Danilova, L. A. (Ed.) (2003). Spravochnik po laboratornym metodam issledovanija [Reference Laboratory Methods]. Saint Petersburg: Piter, 736.
  12. Khabryev, R. U. (Ed.) (2005). Rukovodstvo po eksperimentalnomu (doklinicheskomu) izucheniu novykh farmakolohycheskikh veshchestv [Manual on experimental (preclinical) study of new pharmacological substances]. Moscow, 832.
  13. Palileo, C., Kaunitz, J. D. (2011). Gastrointestinal defense mechanisms. Current Opinion in Gastroenterology, 27 (6), 543–548. doi: 10.1097/mog.0b013e32834b3fcb
  14. Wallace, J. L., Miller, M. J. S. (2000). Nitric oxide in mucosal defense: A little goes a long way. Gastroenterology, 119 (2), 512–520. doi: 10.1053/gast.2000.9304
  15. Soloveva, G. A. (2007). Erozii zheludka – otdelnaia nozolohycheskaia forma ili unyversalnaia reaktsyia slyzystoi obolochki na povrezhdenie? [Erosion of the stomach – a separate nosological form or a universal reaction of the mucous membrane on the damage?]. Internal medicine, 3 (3). Available at: http://www.mif-ua.com/archive/article_print/420
  16. Krejci, V., Hiltebrand, L., Banic, A., Erni, D., Wheatley, A. M., Sigurdsson, G. H. (2000). Continuous measurements of microcirculatory blood flow in gastrointestinal organs during acute haemorrhage. British Journal of Anaesthesia, 84 (4), 468–475. doi: 10.1093/oxfordjournals.bja.a013472
  17. Biletskyi, O. V., Stupnytskyi, M. A. (2010). Oksyd azotu – molekuliarno-biolohichna skladova mekhanizmiv notsytseptsii [Nitric oxide – molecular mechanisms of nociception component]. Medical emergency conditions, 2 (27), 28–34.
  18. Shymanovskyi, N. L., Gurevich, K. S. (2000). Rol' oksida azota v mehanizmah dejstvija lekarstvennyh veshhestv [The role of nitric oxide in the mechanisms of drug action]. International Medical Journal, 1, 104–107.
  19. Mamchur, V. Y., Podpletniaia, E. A., Makarenko, O. V. et. al. (2005). Sovremennye predstavleniia o mekhanizmakh terapevticheskoho i pobochnoho deistviia NPVS [Modern understanding of the mechanisms of therapeutic and side effects of NSAID]. Journal of Pharmacy and Pharmacology, 4, 3–17.
  20. Svyntsytskyi, A. S., Puzanova, O. G. (2002). Gastroduodenal'nye oslozhneniia protivovospalitel'noi terapii v revmatologicheskoi praktike [Gastroduodenal complications of anti-inflammatory therapy in rheumatological practice]. Ukrainian Journal of Rheumatology, 2 (8), 15–23.
  21. Petrovska, G. P. (2004). Farmakokinetyka, analhetychnyi efekt ta toksychnist dyklofenaku natriiu u shchuriv z eksperymentalnym zapalnym protsesom [Pharmacokinetics, analgesic effect and toxicity of diclofenac sodium in rats with experimental inflammation]. Biomedical and Viosocial Anthropology, 3, 87–91.
  22. Renton, K. (2004). Cytochrome P450 Regulation and Drug Biotransformation During Inflammation and Infection. Current Drug Metabolism, 5 (3), 235–243. doi: 10.2174/1389200043335559

Downloads

Published

2017-04-29

How to Cite

Kramar, H. (2017). Experimental study of state of gastric mucosa in rats under introduction of new derivate of 4-[4-oxo-4h-quinazoline-3-yl] benzoic acid (PC-66). ScienceRise: Pharmaceutical Science, (2 (6), 53–58. https://doi.org/10.15587/2519-4852.2017.100549

Issue

Section

Pharmaceutical Science